EPO and Miyoshi myopathy: As infectious complications are considered to be one of the main causes of morbidity and mortality in MM, vaccinations and prophylactic antimicrobial treatment are often associated in the therapeutic protocol [35,36], together with erythropoietin and/or granulocyte colony-stimulating factors to mitigate cytopenias.